(ACAD) ACADIA Pharmaceuticals - Ratings and Ratios
Pimavanserin, Trofinetide
ACAD EPS (Earnings per Share)
ACAD Revenue
Description: ACAD ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system (CNS) disorders and rare diseases. The company has a strong commercial presence with two approved products, NUPLAZID for Parkinsons disease psychosis and DAYBUE for Rett Syndrome.
The companys pipeline is diverse, with multiple programs targeting various CNS disorders, including schizophrenia, Alzheimers disease psychosis, and treatment-resistant depression. Notably, Pimavanserin has completed Phase III trials for treating negative symptoms of schizophrenia, while ACP-204 has completed Phase II trials for Alzheimers disease psychosis. The company has also partnered with Neuren Pharmaceuticals and Stoke Therapeutics to develop novel treatments for rare genetic neurodevelopmental diseases.
From a financial perspective, ACADIA Pharmaceuticals has a market capitalization of approximately $3.79 billion, indicating a moderate-sized biotech company. The companys return on equity (RoE) is 35.32%, suggesting a relatively strong return on shareholder investment. However, the forward price-to-earnings (P/E) ratio is 51.28, which may indicate high growth expectations. To further evaluate the companys prospects, key performance indicators (KPIs) such as revenue growth, research and development (R&D) expenses, and cash reserves should be monitored. For instance, the companys ability to maintain a strong revenue growth trajectory, driven by sales of its commercial products, will be crucial in supporting its R&D efforts and pipeline development.
In terms of potential catalysts, upcoming milestones include the readout of clinical trials for ACP-204 and ACP-211, as well as the potential approval of new indications for Pimavanserin. Investors should also keep a close eye on the companys cash burn rate and its ability to secure additional funding to support its pipeline development. By closely monitoring these KPIs and catalysts, investors can gain a better understanding of ACADIA Pharmaceuticals prospects and make more informed investment decisions.
ACAD Stock Overview
| Market Cap in USD | 3,983m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2004-05-27 |
ACAD Stock Ratings
| Growth Rating | 41.4% |
| Fundamental | 62.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 25.6% |
| Analyst Rating | 3.95 of 5 |
ACAD Dividends
Currently no dividends paidACAD Growth Ratios
| Growth Correlation 3m | 81.7% |
| Growth Correlation 12m | 74.7% |
| Growth Correlation 5y | -35.4% |
| CAGR 5y | 12.46% |
| CAGR/Max DD 3y | 0.22 |
| CAGR/Mean DD 3y | 0.39 |
| Sharpe Ratio 12m | -0.36 |
| Alpha | 0.00 |
| Beta | 0.977 |
| Volatility | 45.78% |
| Current Volume | 1617.9k |
| Average Volume 20d | 2008.7k |
| Stop Loss | 23.2 (-4.1%) |
| Signal | 0.06 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (222.2m TTM) > 0 and > 6% of Revenue (6% = 61.1m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 6.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 61.88% (prev 43.91%; Δ 17.97pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 187.9m <= Net Income 222.2m (YES >=105%, WARN >=100%) |
| Net Debt (44.6m) to EBITDA (34.4m) ratio: 1.29 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.91 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (168.7m) change vs 12m ago 1.51% (target <= -2.0% for YES) |
| Gross Margin 91.97% (prev 91.72%; Δ 0.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 95.24% (prev 97.42%; Δ -2.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -7.82
| (A) 0.51 = (Total Current Assets 960.6m - Total Current Liabilities 330.0m) / Total Assets 1.23b |
| (B) -1.76 = Retained Earnings (Balance) -2.16b / Total Assets 1.23b |
| warn (B) unusual magnitude: -1.76 — check mapping/units |
| (C) 0.02 = EBIT TTM 26.3m / Avg Total Assets 1.07b |
| (D) -5.35 = Book Value of Equity -2.16b / Total Liabilities 403.2m |
| Total Rating: -7.82 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.02
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 5.16% = 2.58 |
| 3. FCF Margin 18.36% = 4.59 |
| 4. Debt/Equity 0.49 = 2.38 |
| 5. Debt/Ebitda 11.71 = -2.50 |
| 6. ROIC - WACC (= -5.73)% = -7.17 |
| 7. RoE 30.67% = 2.50 |
| 8. Rev. Trend 90.21% = 6.77 |
| 9. EPS Trend 67.44% = 3.37 |
What is the price of ACAD shares?
Over the past week, the price has changed by +1.68%, over one month by -3.43%, over three months by +6.14% and over the past year by +48.83%.
Is ACADIA Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACAD is around 23.71 USD . This means that ACAD is currently overvalued and has a potential downside of -2.02%.
Is ACAD a buy, sell or hold?
- Strong Buy: 7
- Buy: 6
- Hold: 6
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the ACAD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.3 | 25.3% |
| Analysts Target Price | 30.3 | 25.3% |
| ValueRay Target Price | 26.4 | 9% |
Last update: 2025-09-16 04:30
ACAD Fundamental Data Overview
CCE Cash And Equivalents = 762.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 17.7519
P/E Forward = 22.9358
P/S = 3.9095
P/B = 4.8436
P/EG = -0.42
Beta = 0.754
Revenue TTM = 1.02b USD
EBIT TTM = 26.3m USD
EBITDA TTM = 34.4m USD
Long Term Debt = 73.1m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 330.0m USD (from totalCurrentLiabilities, last quarter)
Debt = 403.2m USD (Calculated: Short Term 330.0m + Long Term 73.1m)
Net Debt = 44.6m USD (from netDebt column, last quarter)
Enterprise Value = 3.62b USD (3.98b + Debt 403.2m - CCE 762.0m)
Interest Coverage Ratio = unknown (Ebit TTM 26.3m / Interest Expense TTM 0.0)
FCF Yield = 5.16% (FCF TTM 187.1m / Enterprise Value 3.62b)
FCF Margin = 18.36% (FCF TTM 187.1m / Revenue TTM 1.02b)
Net Margin = 21.80% (Net Income TTM 222.2m / Revenue TTM 1.02b)
Gross Margin = 91.97% ((Revenue TTM 1.02b - Cost of Revenue TTM 81.8m) / Revenue TTM)
Tobins Q-Ratio = -1.68 (set to none) (Enterprise Value 3.62b / Book Value Of Equity -2.16b)
Interest Expense / Debt = 2.25% (Interest Expense 9.07m / Debt 403.2m)
Taxrate = 12.25% (31.6m / 258.1m)
NOPAT = 23.1m (EBIT 26.3m * (1 - 12.25%))
Current Ratio = 2.91 (Total Current Assets 960.6m / Total Current Liabilities 330.0m)
Debt / Equity = 0.49 (Debt 403.2m / last Quarter total Stockholder Equity 822.4m)
Debt / EBITDA = 11.71 (Net Debt 44.6m / EBITDA 34.4m)
Debt / FCF = 2.16 (Debt 403.2m / FCF TTM 187.1m)
Total Stockholder Equity = 724.4m (last 4 quarters mean)
RoA = 18.13% (Net Income 222.2m, Total Assets 1.23b )
RoE = 30.67% (Net Income TTM 222.2m / Total Stockholder Equity 724.4m)
RoCE = 3.29% (Ebit 26.3m / (Equity 724.4m + L.T.Debt 73.1m))
RoIC = 3.18% (NOPAT 23.1m / Invested Capital 724.4m)
WACC = 8.92% (E(3.98b)/V(4.39b) * Re(9.62%)) + (D(403.2m)/V(4.39b) * Rd(2.25%) * (1-Tc(0.12)))
Shares Correlation 3-Years: 78.79 | Cagr: 0.38%
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 63.68% ; FCFE base≈144.4m ; Y1≈94.8m ; Y5≈43.4m
Fair Price DCF = 3.97 (DCF Value 669.5m / Shares Outstanding 168.7m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 67.44 | EPS CAGR: 35.80% | SUE: 0.09 | # QB: 0
Revenue Correlation: 90.21 | Revenue CAGR: 29.23% | SUE: N/A | # QB: None
Additional Sources for ACAD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle